Publicacions en col·laboració amb investigadors/es de Hospital Universitari de Bellvitge (36)

2025

  1. Late gadolinium enhancement and outcome of cardiac resynchronization therapy in non-ischemic cardiomyopathy

    International Journal of Cardiology, Vol. 418

2024

  1. Factors associated with disease progression in patients with atrial fibrillation and heart failure anticoagulated with rivaroxaban

    Clinical Cardiology, Vol. 47, Núm. 2

  2. Ramipril After Transcatheter Aortic Valve Implantation in Patients Without Reduced Ejection Fraction: The RASTAVI Randomized Clinical Trial

    Journal of the American Heart Association, Vol. 13, Núm. 19, pp. e035460

  3. Spanish cardiac catheterization and coronary intervention registry. 33rd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2023)

    Revista Espanola de Cardiologia, Vol. 77, Núm. 11, pp. 936-946

2023

  1. Cardiac amyloidosis and left atrial appendage closure. The CAMYLAAC study

    Revista Espanola de Cardiologia, Vol. 76, Núm. 7, pp. 503-510

  2. Cardiogenic shock code 2023. Expert document for a multidisciplinary organization that allows quality care

    Revista Espanola de Cardiologia, Vol. 76, Núm. 4, pp. 261-269

  3. Coronary Obstruction After Transcatheter Aortic Valve Replacement: Insights From the Spanish TAVI Registry

    JACC: Cardiovascular Interventions, Vol. 16, Núm. 10, pp. 1208-1217

  4. Spanish cardiac catheterization and coronary intervention registry. 32nd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2022)

    Revista Espanola de Cardiologia, Vol. 76, Núm. 12, pp. 1021-1031

2022

  1. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial

    European Heart Journal, Vol. 43, Núm. 29, pp. 2783-2797

  2. Impact of operatoŕs experience on peri-procedural outcomes with Watchman FLX: Insights from the FLX-SPA registry

    IJC Heart and Vasculature, Vol. 38

  3. Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial

    European Journal of Heart Failure, Vol. 24, Núm. 3, pp. 581-588

  4. VA-ECMO support in patients with refractory cardiogenic shock. A 6-year multicenter registry

    REC: CardioClinics, Vol. 57, Núm. 1, pp. 7-13

2021

  1. Consequences of canceling elective invasive cardiac procedures during Covid-19 outbreak

    Catheterization and Cardiovascular Interventions, Vol. 97, Núm. 5, pp. 927-937

  2. Impact of Comorbidities and Antiplatelet Regimen on Platelet Reactivity Levels in Patients Undergoing Transcatheter Aortic Valve Implantation

    Journal of cardiovascular pharmacology, Vol. 78, Núm. 3, pp. 463-473

  3. Impact of diabetes in patients waiting for invasive cardiac procedures during COVID-19 pandemic

    Cardiovascular Diabetology, Vol. 20, Núm. 1

  4. Persistent pulmonary hypertension in corrected valvular heart disease: Hemodynamic insights and long-term survival

    Journal of the American Heart Association, Vol. 10, Núm. 2, pp. 1-21

  5. ST-Segment Elevation Myocardial Infarction Following Transcatheter Aortic Valve Replacement

    Journal of the American College of Cardiology, Vol. 77, Núm. 17, pp. 2187-2199

  6. Sex differences in the management of patients with acute coronary syndrome: A population-based ecological cross-sectional study in Spain

    REC: CardioClinics, Vol. 56, Núm. 3, pp. 168-178

  7. Spanish Cardiac Catheterization and Coronary Intervention Registry. 30th Official Report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2020) in the year of the COVID-19 pandemic

    Revista Espanola de Cardiologia, Vol. 74, Núm. 12, pp. 1096-1106

2020

  1. Consensus document of the Interventional Cardiology and Heart Rhythm Associations of the Spanish Society of Cardiology on the management of invasive cardiac procedure rooms during the COVID-19 coronavirus outbreak

    REC: Interventional Cardiology, Vol. 2, Núm. 2, pp. 106-111